Gastric Cancer Therapy Market Analysis: $6.39 Billion by 2029 With a CAGR of 9.1%

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

Gastric Cancer Therapy Market Value Projection: How Much Will the Market Size by 2025?
There has been strong expansion in the gastric cancer therapy market size in the past few years. The market is projected to increase from $4.12 billion in 2024 to $4.50 billion in 2025, witnessing a compound annual growth rate (CAGR) of 9.3%. Factors contributing to this growth in the historical period include growing cases of h. pylori infection, escalating tobacco and alcohol use, an expanding elderly population, scarcity of early diagnostic implements, and the extensive use of chemotherapy.

What Will Be the Market Growth Forecat for Gastric Cancer Therapy in 2029?
In the next few years, robust growth is anticipated for the gastric cancer therapy market, which is projected to escalate to a value of $6.39 billion in 2029 with a compound annual growth rate (CAGR) of 9.1%. The increase for the forecasted term could be a result of expansion in biomarker-driven treatments, surge in combined treatment strategies, growth in investment for oncology research and development, enhancement of healthcare infrastructure in developing economies, and the usage of liquid biopsies for monitoring. The prime trends within the predicted term consist of the progress in personalized medicine, concentration on targeted drug delivery systems, rise in clinical trials for unique antibodies, integration of AI in diagnostic imaging, and the evolution of combination therapies.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/gastric-cancer-therapy-global-market-report

What Are the Core Competitive Drivers in the Gastric Cancer Therapy Industry?
The increase in incidences of helicobacter pylori infection is predicted to stimulate the expansion of the gastric cancer therapy market in the future. Helicobacter pylori infection, a bacterial infection primarily targeting the stomach lining, is a prominent instigator of chronic gastritis and gastric cancer. The surge in such infections is largely attributed to unsatisfactory sanitation, as poor hygiene measures along with polluted food or water resources enable the bacteria's transmission via oral-oral or fecal-oral route. By addressing the infection, diminishing the resultant gastric inflammation and cellular harm, and impeding the progression of chronic gastritis and atrophic alterations liable to cause malignant changes in the gastric mucosa, gastric cancer therapy helps decrease the risk of gastric cancer initiated by helicobacter pylori infection. For instance, a report released by the Government of Canada, a Canada-based government administration, in November 2024, states that as of January 2023, the relapse rate of H. pylori infection could be as high as 19%-however, it differs depending on geographical area and age. Therefore, the escalating occurrence of helicobacter pylori infection is fueling the expansion of the gastric cancer therapy market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25767&type=smp

Which Gastric Cancer Therapy Market Segment Is Projected to See the Fastest Growth?
The gastric cancer therapy market covered in this report is segmented -

1) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery
2) By Drug Class: Cytotoxic Agents, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Checkpoint Inhibitors, Miscellaneous Agents
3) By Administration Route: Oral, Intravenous, Intramuscular, Subcutaneous
4) By Stage of Disease: Early Stage, Locally Advanced Stage, Metastatic Stage
5) By End User: Hospitals, Oncology Clinics, Ambulatory Surgical Centers, Research Institutions, Home Care Settings

Subsegments:
1) By Chemotherapy: Neoadjuvant Chemotherapy (NAC), Adjuvant Chemotherapy (AC), Palliative Chemotherapy (PC), Combination Chemotherapy, Monotherapy
2) By Targeted Therapy: Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapy, Vascular Endothelial Growth Factor (VEGF) Inhibitors, Fibroblast Growth Factor Receptor (FGFR) Inhibitors, Mesenchymal-Epithelial Transition (MET) Inhibitors, Claudin 18 Isoform 2 Inhibitors
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer, Cytokine Therapy, Combination Immunotherapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Three-Dimensional Conformal Radiation Therapy (3D-CRT), Brachytherapy
5) By Surgery: Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Subtotal Gastrectomy, Total Gastrectomy, Lymphadenectomy

Which Trends Are Opening New Opportunities in the Gastric Cancer Therapy Market?
Significant players in the gastric cancer therapy market are turning their attention towards the creation of groundbreaking treatments, like combination therapy, to enhance treatment effectiveness and patient results. Combination therapy employs two or more treatments concurrently, such as chemotherapy, targeted therapy, or immunotherapy, to boost total effectiveness. For example, in December 2024, a pharmaceutical firm formerly known as BeiGene, BeOne Medicines Ltd. based in China, received endorsement from the U.S. Food and Drug Administration (FDA) for the use of Tevimbra (tislelizumab-jsgr) in conjunction with platinum- and fluoropyrimidine-based chemotherapy for the initial treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with PD-L1 (=1) expressed tumors. The approval was based on results from the Phase 3 RATIONALE-305 trial, which showed that the combination therapy greatly extended the median overall survival rate to 15.0 months from 12.9 months with chemotherapy alone, equating to a 20% decrease in mortality risk. This accomplishment underscores the emerging trend among major pharmaceutical companies to invest in pioneering, multi-modal treatment strategies that incorporate immunotherapy with traditional chemotherapy protocols to improve clinical outcomes, slow disease progression, and boost survival rates among advanced gastric cancer patients.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25767&type=smp

Who Are the Leaders in the Gastric Cancer Therapy Market?
Major companies operating in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc., Imugene Limited, LintonPharm Co. Ltd.

Which Regional Gastric Cancer Therapy Markets Offer the Greatest Growth Potential?
North America was the largest region in the gastric cancer therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out to Us Speak With Our Expert: Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.